Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark N Polizzotto

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Clinical Trials (London, England)|October 11, 2021
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)Daniel D Murray, Abdel G Babiker, Jason V Baker, et al.
Internal Medicine Journal|May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemicPietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Internal Medicine Journal|May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statementGeorgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.
Medrxiv : the Preprint Server for Health Sciences|November 20, 2020
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)Daniel D Murray, Abdel G Babiker, Jason V Baker, et al.
American Journal of Respiratory and Critical Care Medicine|May 17, 2022
Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess RecoveryDavid J Douin, Lianne Siegel, Greg Grandits, et al.
Blood|October 13, 2023
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphomaPietro R Di Ciaccio, Mark N Polizzotto, Kate Cwynarski, et al.
The New England Journal of Medicine|December 28, 2020
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19, Jens D Lundgren, Birgit Grund, et al.
Nature Communications|May 13, 2025
Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCsJulie A I Thoms, Feng Yan, Henry R Hampton, et al.
Annals of Internal Medicine|December 20, 2021
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial, Jens D Lundgren, Birgit Grund, et al.
NEJM Evidence|May 22, 2023
Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV InfectionJens D Lundgren, Abdel G Babiker, Shweta Sharma, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Clinical Trials (London, England)|October 11, 2021
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)Daniel D Murray, Abdel G Babiker, Jason V Baker, et al.
Internal Medicine Journal|May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemicPietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Internal Medicine Journal|May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statementGeorgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.
Medrxiv : the Preprint Server for Health Sciences|November 20, 2020
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)Daniel D Murray, Abdel G Babiker, Jason V Baker, et al.
American Journal of Respiratory and Critical Care Medicine|May 17, 2022
Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess RecoveryDavid J Douin, Lianne Siegel, Greg Grandits, et al.
Blood|October 13, 2023
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphomaPietro R Di Ciaccio, Mark N Polizzotto, Kate Cwynarski, et al.
The New England Journal of Medicine|December 28, 2020
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19, Jens D Lundgren, Birgit Grund, et al.
Nature Communications|May 13, 2025
Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCsJulie A I Thoms, Feng Yan, Henry R Hampton, et al.
Annals of Internal Medicine|December 20, 2021
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial, Jens D Lundgren, Birgit Grund, et al.
NEJM Evidence|May 22, 2023
Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV InfectionJens D Lundgren, Abdel G Babiker, Shweta Sharma, et al.
Pageof 9